Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria.~1. Age more than 18 years~2. Both sexes~3. all races/ethnic groups.~4. Meeting the clinical diagnosis of Parkinson's disease with presence of moderate to severe Parkinson tremor that is refractory to standard medical treatments and which limits the patients functionality and/or poses significant discomfort.~5. Subjects who are able to read, speak, and understand English.~Exclusion Criteria.~1. Existing significant acute medical condition (i.e. cardiovascular, endocrine, hematologic, neoplastic, infectious, or autoimmune disorders) or significant swallowing or breathing difficulties.~2. Pregnancy or planned pregnancy (determined by urine pregnancy test).~3. Active breast feeding.~4. Enrollment in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol.~5. Any subject for whom botulinum toxin treatment would be contraindicated; known allergy or sensitivity to medication.~6. Subjects who are younger than 18 years of age. Neuromuscular-junction disorders.~7. Evidence of acute pathology in neuro-imaging.~8. Axis I diagnosis determined by a neurologist or psychiatrist.~9. Use of Anesthetic medications within two weeks and corticosteroid injections within 4 weeks of enrollment.~10. Those who received botulinum toxin injections in the past 4 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo, then Xeomin (Type: ACTIVE_COMPARATOR): Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
- Xeomin, then Placebo (Type: ACTIVE_COMPARATOR): Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).